Banner (NASDAQ:BANR) Given “Outperform” Rating at Raymond James

Banner (NASDAQ:BANR) Given “Outperform” Rating at Raymond James

Banner (NASDAQ:BANR – Get Free Report)‘s stock had its “outperform” rating reiterated by stock analysts at Raymond James in a research note issued on Monday,Benzinga reports. They currently have a $65.00 price objective on the financial services provider’s stock, down from their prior price objective of $77.00. Raymond James’ price target would suggest a potential […]

Centerspace (NYSE:CSR) Upgraded by Raymond James to Outperform Rating

Centerspace (NYSE:CSR – Get Free Report) was upgraded by research analysts at Raymond James from a “market perform” rating to an “outperform” rating in a note issued to investors on Monday, Marketbeat reports. The firm presently has a $66.00 target price on the stock. Raymond James’ price objective suggests a potential upside of 14.58% from […]

NervGen Pharma is a high-risk, high-reward stock, analyst says

Raymond James analyst Michael W. Freeman thinks NervGen Pharma (NervGen Pharma Corp Stock Quote, Chart, News, Analysts, Financials TSXV:NGEN) is undervalued. In a research update to clients April 8th, the analyst maintained his “Outperform” rating and target price of $4.50 per share on the stock. At a recent event, NervGen highlighted the urgent need for […] Source